Deferasirox Therapy in Children With Fanconi Aplastic Anemia
Journal of Pediatric Hematology/Oncology, 05/14/2012Tunc B et al.
Deferasirox is an oral, easily applicable, and effective iron chelator; baseline hepatotoxicity and nephrotoxicity may increase the development of toxic side effects in children with Fanconi aplastic anemia (FAA). Patients with FAA receiving deferasirox treatment should be followed up closely for these side effects.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.